“Real-world” effectiveness of daily controller medicine in children with mild persistent asthma

This publication has 18 references indexed in Scilit:

• Estimating Treatment Effects From Observational Data
  Published by American Medical Association (AMA) ,2002
• Inhaled corticosteroids plus salmeterol or montelukast: Effects on resource utilization and costs
  Journal of Allergy and Clinical Immunology, 2002
• Economic Impact of Asthma Therapy with Fluticasone Propionate, Montelukast, or Zafirlukast in a Managed Care Population
  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2002
• A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy
  Clinical Therapeutics, 2001
• Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast
  Respiratory Medicine, 2001
• Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.
  Respiratory Medicine, 2001
• One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma
  Journal of Allergy and Clinical Immunology, 2001
• 834 Patients on inhaled fluticasone 44 & 110 ug demonstrate significant reductions in both asthma and total health care costs while zafirlukast increases costs
  Journal of Allergy and Clinical Immunology, 2000
• Comparison of patients' compliance with prescribed oral and inhaled asthma medications
  Archives of internal medicine (1960), 1994
• Pediatric asthma deaths in Victoria: The mild are at risk
  Pediatric Pulmonology, 1992